Get the Stockscreener App
73.47
2.31%
-1.72
Celcuity Inc stock is traded at $73.47, with a volume of 360.72K.
It is down -2.31% in the last 24 hours and up +45.43% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$75.19
Open:
$72.83
24h Volume:
360.72K
Relative Volume:
0.32
Market Cap:
$3.12B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-27.41
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
-1.32%
1M Performance:
+45.43%
6M Performance:
+573.90%
1Y Performance:
+378.22%
1-Day Range:
$72.56
$75.44
1-Week Range:
$71.61
$79.97
52-Week Range:
$7.575
$83.00
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
73.50 | 3.19B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.16 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.15 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.92 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.09 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.56 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity Inc. to Participate in Stifel 2025 Healthcare Conference with CEO Fireside Chat - Quiver Quantitative
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference - GlobeNewswire
How to track smart money flows in Celcuity Inc.July 2025 Update & Free Long-Term Investment Growth Plans - newser.com
Will Celcuity Inc. stock benefit from AI adoption2025 Technical Patterns & Entry and Exit Point Strategies - newser.com
Why analysts upgrade Celcuity Inc. stockJuly 2025 Fed Impact & Free Verified High Yield Trade Plans - newser.com
Sector ETF performance correlation with Celcuity Inc.Recession Risk & Real-Time Market Trend Scan - newser.com
Key resistance and support levels for Celcuity Inc.Gold Moves & Long-Term Growth Portfolio Plans - newser.com
What institutional flow reveals about Celcuity Inc.July 2025 PreEarnings & Growth-Oriented Investment Plans - newser.com
ESMO 2025: Celcuity gets first positive results for Pi3K inhibitor in PiK3CA wild-type HR+/HER2 breast cancer - Yahoo Finance
Candlestick signals on Celcuity Inc. stock todayIPO Watch & Advanced Swing Trade Entry Plans - newser.com
What drives Celcuity Inc stock priceTechnical Analysis Insights & Build Diversified Portfolios With Ease - earlytimes.in
Price action breakdown for Celcuity Inc.Weekly Trend Report & AI Based Trade Execution Alerts - newser.com
How buybacks impact Celcuity Inc. stock valueTrade Signal Summary & Safe Entry Trade Signal Reports - newser.com
Celcuity (CELC) Is Up 11.9% After Revealing Efficacy of Gedatolisib in ESMO Trial Results - simplywall.st
Celcuity : Corporate Presentation (Celcuity Investor Presentation V.7.1.2 Final) - MarketScreener
Celcuity (CELC) Price Target Increased by 10.74% to 84.15 - Nasdaq
When is the best time to exit Celcuity Inc.Oil Prices & Reliable Entry Point Trade Alerts - newser.com
How currency fluctuations impact Celcuity Inc. stockEarnings Beat & Technical Buy Zone Confirmation - newser.com
What analysts say about Celcuity Inc stockVolatility Trading Techniques & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Published on: 2025-10-27 20:00:39 - newser.com
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):